Recently, the journal Clinical Infectious Diseases published a study that stated that Merck's Zoztavax vaccine for the skin condition shingles reduced outbreaks among patients in their fifties by as much as 70%. Shingles is a skin condition caused by the chicken pox virus that largely targets people over fifty. Merck also overcame production difficulties for the vaccine that caused shortages for the growing senior population. Because of the advances in Zoztavax production, Merck recently restored production for the vaccine and aimed to fill back orders caused by its production difficulties.
Herpesvirus image courtesy Russell Kightley Media